Amprius looks expensive and its chart looks more like a short than a long. At just under 18x forward sales on current shares and about 22x fully diluted, versus a 12x fair value for high-growth companies, it is pricey even on a $135 million 2026 revenue estimate above guidance, with a 33 million-share overhang. After earnings it broke its 9, 21 and 50-day averages and was rejected at the falling 21-day, making it a near-term short on rallies, though the quarter itself was good. x.com x.com
